Crucial Commission studies to shape new regulatory practices
This article was originally published in Clinica
The European Commission's agenda for the remainder of 2007 includes several studies critical to tightening up the EU's medtech regulatory act. Items under the spotlight for the next few months will include: reprocessing, counterfeiting, vigilance and the overlap with the Advanced Therapies Medicinal Products Regulation.
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.